Hannah Cohen

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8154127/hannah-cohen-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18 38 1,475 42 g-index h-index citations papers 8.3 4.63 1,922 43 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
42	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021 , 61, 64	3	
41	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021 , 23, 45	4.9	3
40	Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review. <i>Rheumatology</i> , 2021 ,	3.9	1
39	Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. <i>Thrombosis Research</i> , 2021 , 198, 213-221	8.2	12
38	Small Vessel Disease and Ischemic Stroke Risk During Anticoagulation for Atrial Fibrillation After Cerebral Ischemia. <i>Stroke</i> , 2021 , 52, 91-99	6.7	10
37	Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 892-908	15.4	3
36	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Blood</i> , 2021 , 137, 299-309	2.2	7
35	Cerebral Small Vessel Disease and Functional Outcome Prediction After Intracerebral Hemorrhage. <i>Neurology</i> , 2021 , 96, e1954-e1965	6.5	3
34	Coexistent antiphospholipid syndrome and myeloproliferative neoplasm. <i>Lupus</i> , 2021 , 30, 1502-1508	2.6	1
33	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) <i>Lupus</i> , 2021 , 9612033211062523	2.6	3
32	Comparing pregnancy outcomes in patients with criteria and non-criteria autoimmune disease: A systematic review. <i>Lupus</i> , 2021 , 9612033211061850	2.6	O
31	The assessment of patients with the antiphospholipid antibody syndrome: where are we now?. <i>Rheumatology</i> , 2020 , 59, 1489-1494	3.9	2
30	The prevalence of incidental uterine venous plexus thrombosis in women attending a gynecology clinic. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2557-2565	15.4	2
29	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102525	13.6	13
28	Use of direct oral anticoagulants in antiphospholipid syndrome: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 259-261	15.4	5
27	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology,the</i> , 2020 , 7, e613-e623	14.6	4
26	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020 , 29, 1571-1593	2.6	27

(2016-2020)

25	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation.	15.4	57
24	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2126-2137	15.4	30
23	Association of enlarged perivascular spaces and anticoagulant-related intracranial hemorrhage. <i>Neurology</i> , 2020 , 95, e2192-e2199	6.5	6
22	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020 , 39, 100610	11.1	42
21	Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020	15.4	38
20	, 18, 1569-1575 The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 464-4	€8 ³	38
19	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2069-2080	15.4	4
18	Clinical and laboratory practice for lupus anticoagulant testing: An International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1715-1732	15.4	16
17	Pathogenesis of Antiphospholipid Antibody Syndrome 2019 , 324-337		3
16	Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 320-325	5.5	31
15	Under crossfire: thromboembolic risk in systemic lupus erythematosus. <i>Rheumatology</i> , 2019 , 58, 940-95	2 3.9	13
14	Cognitive Impairment Before Intracerebral Hemorrhage Is Associated With Cerebral Amyloid Angiopathy. <i>Stroke</i> , 2018 , 49, 40-45	6.7	30
13	Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. <i>Lancet Neurology, The</i> , 2018 , 17, 539-547	24.1	134
12	HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or	5.3	60
11	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. <i>Current Rheumatology Reports</i> , 2017 , 19, 50	4.9	5
10	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report 2017 , 317-338		16
9	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis 2017 , 77-116		3
8	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. <i>Lancet Haematology,the</i> , 2016 , 3, e426-36	14.6	231

7	Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 651-8	7	68
6	Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. <i>Neurology</i> , 2016 , 86, 360-6	6.5	88
5	Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. <i>Thrombosis Research</i> , 2015 , 135, 1191-7	8.2	23
4	Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 13-9	7	58
3	The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods. <i>International Journal of Stroke</i> , 2015 , 10 Suppl A100, 155-61	6.3	44
2	14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. <i>Autoimmunity Reviews</i> , 2014 , 13, 685-96	13.6	248
1	Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. <i>British Journal of Haematology</i> , 2005 , 128, 242-7	4.5	91